Skip to main content
. Author manuscript; available in PMC: 2018 Mar 15.
Published in final edited form as: J Immunol. 2017 Feb 3;198(6):2500–2512. doi: 10.4049/jimmunol.1601778

Figure 4. miR-29a activates human PBMCs and DCs via TLR8.

Figure 4

(A) Human PBMCs (n=9) from healthy donors were treated with DOTAP-miR29a, DOTAP-miR-16, DOTAP alone for 48 hrs. T cell activation was measured by CD69 upregulation on CD3+ T cells by flow cytometry. (B) CD11c+ CD14- human dendritic cells (n=5) were treated with DOTAP-miR29a, DOTAP-miR-16, DOTAP alone for 48 hrs. DC maturation was assessed by mean fluorescence intensity (MFI) of CD40 and CD83 by FACS and (C) Detection of TNF-a and IL-6 in supernatants by ELISA. (D) Human dendritic cells were transfected with Flag TLR8 or Flag EV plasmids with or without Scr or miR-29a or miR-155. Immunoprecipitation was carried out using IgG or Flag Antibody and RNA-IP showing enrichment of only miR-29a in TLR8 transfected cells. Paired t-test was used to compare differences, p<0.05 was considered significant.